I think the 1.5-2x XR did not include AG deal with Prasco. I could be wrong, but I would expect much more revenue to come from this partnership than what we were previously doing with ER under Lannett.
I’m hoping to hear initial FDA response re: oxy by mid-year depending on when clock started for PDUFA (May/Jun 2024?), assuming no CRLs/issues.